Novartis Buys Rights to Intecell's Japanese Encephalitis Vaccine Candidate
Filed in archive Corporate and Industrial News , Drugs, Vaccines and Therapeutics by ruth on June 14, 2006

.Intercell recently announced favorable results for IC51 in Phase III clinical trials and the vaccine is currently under regulatory review in Europe with an orphan drug status.
Further details from Market Watch.
Permalink: Novartis Buys Rights to Intecell's Japanese Encephalitis Vaccine Candidate
Tags:
vaccine
encephalitis
biotech
novartis
rights
japanese+encephalitis
vaccine+candidate
novartis+buys
Trackback: http://www.creative-weblogging.com/cgi-bin/mt-tb.pl/24761

Mr Wong
